Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
This promotional webinar has been developed and funded by Lilly. Lilly products will be discussed at this online event and prescribing information can be found on the platform. OmniaMed Communications has provided editorial, marketing and logistical support. Lilly is a registered trademark of Eli Lilly and Company © 2021 Eli Lilly and Company. All rights reserved.

Prescribing information and adverse event reporting information for Trulicity® (dulaglutide) can be accessed by clicking here
For more information about Trulicity® (dulaglutide) please visit: www.lillydiabetes.co.uk (UK only)

Trulicity® (dulaglutide): Significant efficacy, simply achieved, and higher dose data

Trulicity is indicated for the treatment of adults with
insufficiently controlled type 2 diabetes mellitus as an
adjunct to diet and exercise:

  • As monotherapy when metformin is considered
    inappropriate due to intolerance or contraindications.
  • In addition to other medicinal products for the treatment of diabetes

Adverse event reporting information can be found at the bottom of the page.

Next event starting shortly

Not registered? Register now

ABOUT THE WEBINAR

Trulicity® (dulaglutide): Significant efficacy, simply achieved, and higher dose data

Trulicity (dulaglutide) is a once weekly injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) with proven efficacy in reducing HbA1c in adults with type 2 diabetes.1 The REWIND study demonstrated cardiovascular benefits for Trulicity reducing the risk of major cardiovascular events, in a broad type 2 diabetes population.2

This live webinar will take place on 10 September 2021 at 13:00. The session faculty will consist of Dr Shahzada Khan (Chair) and the key-note speaker Dr Akhila Mallipedhi. Dr Mallipedhi will consider the clinical trial data supporting Trulicity (dulaglutide) in treating people with type 2 diabetes2 and examine the practicalities of initiating this medication in the same population. There will also be a look at the Trulicity (dulaglutide) higher dose data provided by the AWARD-11 trial3. Throughout the webinar there will be ample opportunity to submit questions to be answered during the live Q&A following the broadcast.

  1. Kugler AJ, et al. Diabetes Metab Syndr Obes. 2018; 11: 187–197
  2. Gerstein HC, et al. The Lancet 2020;8(2): 106-114.
  3. Frias JP, et al. Diabetes Care. 2021 Mar;44(3):765-773

WHAT DOES THIS PROGRAMME OFFER?

1

2

3

Agenda

Trulicity® (dulaglutide): Significant efficacy, simply achieved, and higher dose data

Trulicity® (dulaglutide): Significant efficacy, simply achieved, and higher dose data

Live Q&A

Speakers

Dr Shahzada Khan (Chair)

GP Principle, Newham, East London

Dr Akhila Mallipedhi

Consultant in Diabetes, Prince Phillip Hospital, Llanelli

Trulicity® (dulaglutide): Significant efficacy, simply achieved, and higher dose data

This promotional webinar has been developed and funded by Lilly. Lilly products will be discussed at this online event and prescribing information can be found on the platform. OmniaMed Communications has provided editorial, marketing and logistical support. Lilly is a registered trademark of Eli Lilly and Company © 2021 Eli Lilly and Company. All rights reserved.

Prescribing information and adverse event reporting information for Trulicity® (dulaglutide) can be accessed by clicking here
For more information about Trulicity® (dulaglutide) please visit: www.lillydiabetes.co.uk (UK only)

Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.

For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.